Huang Deliang
Huang Deliang

Position: Director of Endemic Area on the 7th Floor

Title: Associate Chief Physician

Specialty: Director Huang is good at medical oncology, especially treatment for breast cancer, lymphoma.

Consult Now


Director Huang Deliang graduated from Guangxi Medical University, major in clinical medicine science. During 2007 to 2008, he engaged in advanced studies in Sun Yet-Sen University Cancer Hospital. With 11 years of clinical work engagement, he is proficient in various minimally invasive technologies, such as deep tissue biopsy with CT guidance, deep vein catheterization, serous cavity hyperthermic perfusion therapy, radiofrequency ablation, radioactive particle implantation, analgesia pump implantation etc. Especially, he has abundant clinical experience in chemotherapy, endocrinotherapy, biological targeted therapy etc. Besides, he published more than 10 excellent papers in national research journals of various levels.

Education Background

From September 2007 to October 2008, Director Huang engaged in advanced studies on medical oncology and invasive technology at Sun Yat-Sen University Cancer Hospital.

Medical Experience

In 2009, Director Huang was awarded “Outstanding Youth of Medical Technology in Lianjiang”.

In 2011, he was rated as one of the “Ten Outstanding Young Doctors in Zhanjiang”.

His research project, The Efficacy Correlation between Recombinant Human Endostatin and GSTP1 Mononucleotide Polymorphism of Advanced Non-Small Cell Lung Cancer, won excellent achievement prize of science and technology program in Zhanjiang.

He has linear accelerator therapist and CT physician qualifications.

Academic Achievement

National Medical Frontiers of China, vol.8, no.4, Feb. 2013, lead author

Chinese and Foreign Medical Research, vol.11, no.4, Apr. 2013, lead author

Chinese Journal of Modern Drug Application, vol.7, no.14, Jul. 2013, lead author

The leader of research subject of Zhanjiang Science and Technology Bureau, The Efficacy Correlation between Recombinant Human Endostatin and GSTP1 Mononucleotide Polymorphism of Advanced Non-Small Cell Lung Cancer.

The Effect of tanshinone on Cerebral Infarction Patient’s Neuropeptide Y

Analysis of Platinum Resistance Gene in the Case of Advanced Non-Small Cell Lung Cancer

Research Technology

Minimally invasive targeted treatment for solid tumors


Combination of TCM & Western Medicine Therapy

Research Area


Other doctors in St. Stamford Modern Cancer Hospital Guangzhou

*Surgery, in addition to the appropriate chemotherapy and radiotherapy, are effective in treating early cancer, but certain patients in late stage of cancer may not be tolerate surgery well as they can be relatively weak. A combination of carefully planned minimally invasive therapy, chemotherapy or radiotherapy can effectively reduce the side effects and discomfort of treatment and may help patient get better efficacy.

Location of Offices
Frequently Asked Questions (FAQ)
Attend cancer symposiums